934557-65-0

Basic information

• Product Name: 2-(Bromomethyl)-5-(methylsulphonyl)benzotrifluoride
• Synonyms: 2-(Bromomethyl)-5-(methylsulphonyl)benzotrifluoride;4-(Methylsulphonyl)-2-(trifluoromethyl)benzyl bromide 98%;2-(Bromomethyl)-5-(methylsulphonyl)benzotrifluoride, 1-(Bromomethyl)-4-(methylsulphonyl)-2-(trifluoromethyl)benzene, 4-(Bromomethyl)-3-(trifluoromethyl)phenyl methyl sulphone;4-(Methylsulphonyl)-2-(trifluoromethyl)benzylbromide98%;2-(Bromomethyl)-5-(methylsulfonyl)benzotrifluoride;1-(bromomethyl)-2-(trifluoromethyl)-4-(methylsulfonyl)benzene;1-(bromomethyl)-4-methylsulfonyl-2-(trifluoromethyl)benzene;ONSMWCRBEGDPIL-UHFFFAOYSA-N
• CAS NO: 934557-65-0
• Molecular Formula: C₉H₈BrF₃O₂S
• Molecular Weight: 317.1228296
• Mol File: 934557-65-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 360.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.632±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-(Bromomethyl)-5-(methylsulphonyl)benzotrifluoride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(Bromomethyl)-5-(methylsulphonyl)benzotrifluoride(934557-65-0)
• EPA Substance Registry System: 2-(Bromomethyl)-5-(methylsulphonyl)benzotrifluoride(934557-65-0)

Safety Data

• Hazardous Substances Data: 934557-65-0(Hazardous Substances Data)

Usage

General Description

2-(Bromomethyl)-5-(methylsulphonyl)benzotrifluoride is a chemical compound with the molecular formula C8H7BrF3O2S. It is an organofluorine compound that consists of a benzene ring substituted with a bromomethyl group and a methylsulphonyl group. 2-(Bromomethyl)-5-(methylsulphonyl)benzotrifluoride is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also used as a building block in the production of various specialty chemicals and fine chemicals. 2-(Bromomethyl)-5-(methylsulphonyl)benzotrifluoride is a versatile compound that is important for the development of new materials and products in the chemical industry.

Upstream product

• 1215310-75-0 4-(methylsulfonyl)-2-(trifluoromethyl)benzaldehyde oxime 
• 886496-75-9 1-(bromomethyl)-4-chloro-2-(trifluoromethyl)benzene 
• 20277-69-4 sodium methansulfinate 
• 1312704-87-2 (4-Methylsulfanyl-2-trifluoromethyl-phenyl)-methanol 
• 1289164-55-1 4-methylsulfanyl-2-(trifluoromethyl)benzaldehyde 
• 90176-80-0 2-(trifluoromethyl)-4-fluorobenzaldehyde 
• 1215323-17-3 (4-(methylsulfonyl)-2-(trifluoromethyl)phenyl)methanol 

Downstream Products

• 872365-14-5 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridine-3-yl]acetic acid 
• 1312704-88-3 1-(4-methanesulfonyl-2-(trifluoromethyl)benzyl)-1H-indazole-5-carbaldehyde 

Relevant articles and documents

PREPARATION OF 2-[2-METHYL-1-[[4-METHYLSULFONYL-2-(TRIFLUORO METHYL)PHENYL]METHYL] PYRROLO[2,3-B]PYRIDIN-3-YL]ACETIC ACID

The present invention relates to a novel compound of Formula IV and use of said compound for the preparation of 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl] methyl]pyrrolo[2,3-b]pyridine-3-yl]acetic acid [fevipiprant], Formula IV wherein A is SO2Me, halogen or a leaving group. The present invention further relates to a process of preparation of pharmaceutical acceptable salts of fevipiprant and composition thereof.

Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma

Further optimization of an initial DP2 receptor antagonist clinical candidate NVP-QAV680 led to the discovery of a follow-up molecule 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid (compou

AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS

The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.